Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BeiGene Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd., a Swiss corporation, announced the completion of a share purchase under its 2018 Employee Share Purchase Plan (ESPP), allowing eligible employees to buy shares at a 15% discount. A total of 62,962 ADSs, representing 818,506 shares, were purchased by 3,932 participants, equating to approximately 0.05% of the total issued shares. The initiative aims to align employee interests with shareholders and retain talent without performance targets or clawback mechanisms, with 3,179,780 shares still available for future grants.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,668,386
Technical Sentiment Signal: Buy
Current Market Cap: HK$314.5B
For an in-depth examination of 6160 stock, go to TipRanks’ Overview page.